Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass Spectrometry
Open Access
- 18 October 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-11
Abstract
Patient-derived explant (PDE) culture of solid tumors is increasingly being applied to preclinical evaluation of novel therapeutics and for biomarker discovery. In this technique, treatments are added to culture medium and penetrate the tissue via a gelatin sponge scaffold. However, the penetration profile and final concentrations of small molecule drugs achieved have not been determined to date. Here, we determined the extent of absorption of the clinical androgen receptor antagonist, enzalutamide, into prostate PDEs, using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and matrix-assisted laser/desorption ionisation (MALDI) mass spectrometry imaging (MSI). In a cohort of 11 PDE tissues from eight individual patients, LC-MS/MS quantification of PDE homogenates confirmed enzalutamide (10 µM) uptake by all PDEs, which reached maximal average tissue concentration of 0.24–0.50 ng/µg protein after 48 h culture. Time dependent uptake of enzalutamide (50 µM) in PDEs was visualized using MALDI MSI over 24–48 h, with complete penetration throughout tissues evident by 6 h of culture. Drug signal intensity was not homogeneous throughout the tissues but had areas of markedly high signal that corresponded to drug target (androgen receptor)-rich epithelial regions of tissue. In conclusion, application of MS-based drug quantification and visualization in PDEs, and potentially other 3-dimensional model systems, can provide a more robust basis for experimental study design and interpretation of pharmacodynamic data.Keywords
Funding Information
- Cancer Australia (1138766)
- Department of Education and Training | Australian Research Council (FT130101004)
- Cancer Council South Australia (Fellowship)
- Movember Foundation/Prostate Cancer Foundation of Australia
This publication has 44 references indexed in Scilit:
- Prostate Cancer in Primary CareAdvances in Therapy, 2018
- Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant ModelsCold Spring Harbor Perspectives in Medicine, 2018
- Neoadjuvant Enzalutamide Prior to ProstatectomyClinical Cancer Research, 2017
- Contemporary agents in the management of metastatic castration-resistant prostate cancerCanadian Urological Association Journal, 2016
- Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancerExpert Opinion on Pharmacotherapy, 2016
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE TrialJournal of Clinical Oncology, 2016
- Chemotherapy at First Diagnosis of Advanced Prostate Cancer – Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate CancerClinical Oncology, 2016
- Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancerBJU International, 2015
- Androgen-regulated metabolism and biosynthesis in prostate cancerEndocrine-Related Cancer, 2014
- Electrospray and MALDI Mass Spectrometry2010